The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens

CONCLUSIONS: These findings challenge the assumption that oral anti-cancer therapies are universally preferred by patients and demonstrate that there is no "one size fits all" regimen that is preferable to women with ovarian cancer when considering recurrence treatment regimens.PMID:34053748 | DOI:10.1016/j.ygyno.2021.05.022

Source: Gynecologic Oncology - May 31, 2021 Category: Cancer & Oncology Authors: Laura J Havrilesky Amelia L Scott Brittany A Davidson Angeles Alvarez Secord Jui-Chen Yang F Reed Johnson Juan Marcos Gonzalez Shelby D Reed Source Type: research